Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$131.97

0.31 (0.24%)

, XOMA

Xoma

$16.70

(0.00%)

07:41
08/12/19
08/12
07:41
08/12/19
07:41

Xoma adds Janssen Biotech drug candidates to royalty portfolio

XOMA Corporation (XOMA) announced its portfolio of potential future royalty and milestone payments has significantly increased with the addition of Janssen Biotech (JNJ) drug candidates for which XOMA could receive future milestone and royalty payments. In addition, Janssen has elected to accelerate its base annual license fee obligation and will make a one-time $2.5M payment to XOMA. For each program, XOMA is entitled to receive milestone payments upon the achievement of certain clinical development and regulatory approval events. Upon commercialization, XOMA will receive a .75% royalty on net sales.

JNJ

Johnson & Johnson

$131.97

0.31 (0.24%)

XOMA

Xoma

$16.70

(0.00%)

  • 04

    Sep

  • 09

    Sep

  • 16

    Sep

  • 01

    Oct

  • 15

    Oct

JNJ Johnson & Johnson
$131.97

0.31 (0.24%)

07/12/19
RAJA
07/12/19
NO CHANGE
RAJA
Outperform
DOJ investigation of J&J 'not new news,' says Raymond James
Raymond James analyst Jayson Bedford said that "technically" it is not "new news" that the DOJ is investigating Johnson & Johnson's communications around the alleged cancer risks of its talcum powder products as J&J previously disclosed an inquiry in its latest 10-Q filing. He notes J&J has responded to a Bloomberg article on the investigation by stating that there have been no new developments, though this risk was "clearly" underappreciated by investors. Though Bedford still thinks J&J has a strong case, today's reaction is an indication that the talc issue will remain "top-of-mind" and a headline risk, he added. Bedford has an Outperform rating on Johnson & Johnson shares.
07/17/19
MZHO
07/17/19
NO CHANGE
Target $103
MZHO
Buy
Amgen seen by Mizuho as 'most likely' buyer of Celgene's Otezla
In the wake of the recent announcement that Bristol-Myers (BMY) plans to divest Otezla as part of its deal to acquire Celgene (CELG), Mizuho analyst Salim Syed said he has received questions on who could be a realistic buyer. He believes the "most likely" buyer would be Amgen (AMGN), followed by Johnson & Johnson (JNJ), which he would label as a "likely" buyer. Syed identifies the "less likely, but possible" buyers as Eli Lilly (LLY) and Regeneron (REGN). The analyst, who said Otezla is worth anywhere from $5B-$10B depending on the view of sales and synergy potential, keeps a Buy rating and $103 price target on Celgene shares.
07/17/19
RAJA
07/17/19
NO CHANGE
RAJA
Investors shouldn't overreact to drug proposal headlines, says Raymond James
Raymond James analyst Chris Meekins noted that President Donald Trump has indicated an Executive Order on drug pricing is coming soon, but he believes investors "should be cautious not to overreact" to drug related proposal headlines as he "cannot think of a single proposal that was finalized and also survived a court challenge resulting in a negative impact on earnings" yet from the Trump Administration. Given the history of the current White House to date, Meekins said he is increasingly skeptical the Administration will get anything meaningful finalized and overcome legal challenges that will impact drugmakers' earnings before the 2020 election, he tells investors in a healthcare policy note. Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/18/19
PIPR
07/18/19
NO CHANGE
Target $10
PIPR
Overweight
Spring Bank research agreement with NIAID 'smart,' says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes that Spring Bank (SBPH) entered into a research agreement with the National Institute of Allergy and Infectious Diseases, or NIAID, to study preclinical HBV antisense oligonucleotides. With the recent Arrowhead (ARWR) partnership with Janssen (JNJ), the analyst sees this as a "smart development program" building on Spring Bank's HBV expertise. Tenthoff also notes that Spring Bank is conducting the Phase IIb CATALYST 1 and 2 trials of 400mg inarigivir monotherapy/combination with Vemlidy in naive and suppressed HBV patients with preliminary data in the second quarter of 2020, while partner Gilead (GILD) is conducting a Phase II study of inarigivir plus Vemlidy in naive and suppressed HBV patients with initial data likely at AASLD in November. He reiterates an Overweight rating and $10 price target on Spring Bank's shares.
XOMA Xoma
$16.70

(0.00%)

10/19/18
HCWC
10/19/18
NO CHANGE
Target $36
HCWC
Buy
Xoma 'undeservedly and overly punished' after CRL, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered his price target for Xoma (XOMA) to $36 from $49 after the company's partner Novartis (NVS) disclosed the receipt of a Complete Response Letter from the FDA in response to its application for the claim of cardiovascular risk reduction filed for canakinumab. Though canakinumab is one of the lead contributors to Xoma's valuation, the company's shares have been "undeservedly and overly punished," Pantginis tells investors in a research note. He remains focused on Xoma continuing to diversify its risk profile, highlighted by its recent Agenus (AGEN) transaction. He believes the company's numerous "shots on goal" present a "compelling opportunity" at current share levels.

TODAY'S FREE FLY STORIES

ALSN

Allison Transmission

$43.06

-0.96 (-2.18%)

15:30
08/23/19
08/23
15:30
08/23/19
15:30
Conference/Events
Allison Transmission management to meet with RBC Capital »

Meeting to be held In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

15:30
08/23/19
08/23
15:30
08/23/19
15:30
General news
Treasury Action: bond yields have inched up from intraday lows »

Treasury Action: bond…

IWM

iShares Trust Russell 2000 Index Fund

$146.13

-3.92 (-2.61%)

, RUT

Russell 2000 Index

$0.00

(0.00%)

15:22
08/23/19
08/23
15:22
08/23/19
15:22
Technical Analysis
On The Fly: Weekly technical notes for Russell 2000 »

The Russell 2000 (RUT) at…

IWM

iShares Trust Russell 2000 Index Fund

$146.13

-3.92 (-2.61%)

RUT

Russell 2000 Index

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
08/23/19
08/23
15:17
08/23/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
08/23/19
08/23
15:16
08/23/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$12.53

-0.24 (-1.88%)

15:15
08/23/19
08/23
15:15
08/23/19
15:15
Options
Fiat Chrysler put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$285.78

-6.58 (-2.25%)

15:12
08/23/19
08/23
15:12
08/23/19
15:12
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

At time of writing the…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$285.78

-6.58 (-2.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDOG

Datadog

$0.00

(0.00%)

15:11
08/23/19
08/23
15:11
08/23/19
15:11
Syndicate
Datadog files S-1 for IPO, seeks to list on Nasdaq with symbol 'DDOG' »

Datadog filed an S-1 with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIIQ

Health Insurance Innovations

$18.17

-0.87 (-4.57%)

15:05
08/23/19
08/23
15:05
08/23/19
15:05
Options
Health Insurance Innovations call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

  • 20

    Sep

INCY

Incyte

$82.37

-3.2 (-3.74%)

, LLY

Eli Lilly

$110.50

-1.13 (-1.01%)

14:58
08/23/19
08/23
14:58
08/23/19
14:58
Hot Stocks
Eli Lilly, Incyte announce baricitinib meets primary endpoint in Phase 3 trial »

Eli Lilly (LLY) and…

INCY

Incyte

$82.37

-3.2 (-3.74%)

LLY

Eli Lilly

$110.50

-1.13 (-1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Sep

  • 09

    Sep

  • 16

    Sep

  • 02

    Oct

  • 23

    Oct

EPD

Enterprise Products

$28.35

-0.605 (-2.09%)

14:55
08/23/19
08/23
14:55
08/23/19
14:55
Options
Enterprise Products put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

LGF.A

Lionsgate

$10.52

-0.28 (-2.59%)

, LGF.B

Lionsgate

$10.01

-0.205 (-2.01%)

14:54
08/23/19
08/23
14:54
08/23/19
14:54
On The Fly
Box Office Battle: 'Angel has Fallen' looking to swoop into top spot »

Welcome to "Box Office…

LGF.A

Lionsgate

$10.52

-0.28 (-2.59%)

LGF.B

Lionsgate

$10.01

-0.205 (-2.01%)

SNE

Sony

$53.87

-0.91 (-1.66%)

CMCSA

Comcast

$42.75

-1.01 (-2.31%)

CMCSK

Comcast

$0.00

(0.00%)

T

AT&T

$34.95

-0.44 (-1.24%)

CBS

CBS

$42.02

-1.43 (-3.29%)

DIS

Disney

$133.09

-2.98 (-2.19%)

VIA

Viacom

$27.31

-0.28 (-1.01%)

VIAB

Viacom

$25.01

-0.85 (-3.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 05

    Sep

  • 05

    Sep

  • 10

    Sep

  • 11

    Sep

  • 23

    Oct

  • 27

    Oct

QSR

Restaurant Brands

$76.37

0.94 (1.25%)

14:45
08/23/19
08/23
14:45
08/23/19
14:45
Options
Restaurant Brands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:45
08/23/19
08/23
14:45
08/23/19
14:45
General news
Fed funds futures surge on the downdraft in stocks »

Fed funds futures surge…

OSW

OneSpaWorld

$15.84

-0.22 (-1.37%)

14:41
08/23/19
08/23
14:41
08/23/19
14:41
Conference/Events
OneSpaWorld management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 28

    Aug

OPRX

OptimizeRx

$15.16

-0.39 (-2.51%)

14:38
08/23/19
08/23
14:38
08/23/19
14:38
Conference/Events
OptimizeRx management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 12

    Sep

APPN

Appian

$60.63

0.29 (0.48%)

14:37
08/23/19
08/23
14:37
08/23/19
14:37
Conference/Events
Appian management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 27

    Aug

ET

Energy Transfer LP

$13.35

-0.31 (-2.27%)

14:35
08/23/19
08/23
14:35
08/23/19
14:35
Options
Energy Transfer put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKTR

Nektar

$17.04

0.05 (0.29%)

14:25
08/23/19
08/23
14:25
08/23/19
14:25
Options
Nektar call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

14:20
08/23/19
08/23
14:20
08/23/19
14:20
General news
Treasury Action: yields remain sharply lower on a flight to safety »

Treasury Action: yields…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
08/23/19
08/23
14:17
08/23/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBGI

Sinclair Broadcast

$43.19

-1.24 (-2.79%)

, DIS

Disney

$133.27

-2.8 (-2.06%)

14:16
08/23/19
08/23
14:16
08/23/19
14:16
Periodicals
Sinclair CEO eyes more regional sports network acquisitions, WSJ reports »

Sinclair Broadcast (SBGI)…

SBGI

Sinclair Broadcast

$43.19

-1.24 (-2.79%)

DIS

Disney

$133.27

-2.8 (-2.06%)

T

AT&T

$34.97

-0.425 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 10

    Sep

  • 11

    Sep

  • 23

    Sep

  • 23

    Oct

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
08/23/19
08/23
14:16
08/23/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FANG

Diamondback Energy

$95.83

-3.315 (-3.34%)

14:15
08/23/19
08/23
14:15
08/23/19
14:15
Options
Diamondback Energy put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 11

    Sep

14:10
08/23/19
08/23
14:10
08/23/19
14:10
General news
Action Economics Survey results: »

Action Economics Survey…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.